NEW YORK, Nov. 2, 2015 /PRNewswire/ -- S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men, today announced that Nicolas Sitchon, CEO of S1 Biopharma, will present at the BIO-Europe 2015 Conference on Tuesday, November 3, 2015 at the International Congress Center in Munich, Germany. Mr. Sitchon will present an update on the company's clinical stage development programs targeting treatment of diminished sexual desire in women and men, beginning at 11:15 AM in Room 2 on Level 0.
Mr. Sitchon will provide an overview of the clinical development programs for all of the company's pipeline products including its lead product candidate, Lorexys®, currently in a phase 2B clinical trial for treatment of HSDD. Lorexys is an investigational non-hormonal central nervous system (CNS) therapy designed to restore the balance of key neurotransmitters in the brain that affect sexual desire.
About S1 Biopharma, Inc.
S1 Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of sexual dysfunction in both women and men. The company's development programs include first-in-class non-hormonal therapies designed to treat diminished sexual desire by restoring the natural balance of key neurotransmitters in the brain. The company's lead product candidate, Lorexys, is currently in a Phase 2a clinical trial for the treatment of hypoactive sexual desire disorder (HSDD) in women. S1 Biopharma is evaluating partnerships, collaborations and out-licensing deals that will enable the company to rapidly advance its sexual dysfunction franchise as well as to accelerate the path to commercialization for its drug candidates in the U.S. and internationally. For more information, visit http://s1biopharma.com/ or follow S1 Biopharma on Facebook or Twitter (@s1biopharma).
S1 Biopharma, Inc.
7 World Trade Center
250 Greenwich St., 46th Floor
New York City, NY 10007
Berry & Company Public Relations
SOURCE S1 Biopharma, Inc.